Enjoy complimentary customisation on priority with our Enterprise License!
It has been observed that axillary hyperhidrosis is a medical condition in which the body produces excessive sweat in the underarms. The individuals with axillary hyperhidrosis sweat up to five times the amount that is necessary to regulate the body temperature. The causes of axillary hyperhidrosis can be genetic, so if a family member suffers from the condition, the person is more likely to inherit it. High consumption of caffeine is also one of the causes of axillary hyperhidrosis. This condition usually tends to begin during the onset of puberty, but symptoms can appear up to the age of 25 years. Antiperspirants are considered the most efficient approach for the treatment of axillary hyperhidrosis.
According to this pipeline analysis report, all of the drug molecules in the pipeline are being developed for axillary hyperhidrosis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Want a bigger picture? Try a FREE sample of this report now!
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of axillary hyperhidrosis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in our pipeline analysis report are:
The topical route of administration (ROA) involves the application of the drug molecules directly on the skin, which will have a more direct effect on the target cells.
According to the pipeline analysis report, most of the molecules that are currently in the drug pipeline for axillary hyperhidrosis are being targeted on muscarinic acetylcholine receptors and most of these molecules are in the pre-clinical stage of development.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.